FranceHealthcare and life sciences2020 – ongoingOSE Immunotherapeutics
MAbSilico AI software for antibody discovery and design
OSE Immunotherapeutics widened its use of MAbSilico AI software from 6 antibody programs to 16
Problem
Antibody drug candidates often fail late in development, and preclinical work is slow. OSE wanted to lower that risk and speed up its antibody programs.
Approach
OSE began working with MAbSilico in early 2020 on 6 programs. The software combines AI, numerical simulation and data mining, from choosing a target epitope through to optimizing a humanized lead. In January 2021 the agreement was expanded by 10 programs. The tools were also used to identify vaccine target epitopes for CoVepiT, and the two companies planned a joint design platform that combines OSE's database with MAbSilico's tools.
Results
Takeaway
OSE extended the collaboration after a year, but the release reports no efficacy results from the designed antibodies.
Categories
- Size
- Small business
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Partner co-development
- Evidence
- Company's own claim
Sources
Source summaries
The press release says OSE started with 6 programs in early 2020 and added 10 more. It lists the MAbSilico tools used and says CoVepiT vaccine epitopes were identified in about two weeks. It gives no efficacy data.
Full details are in the original sources.
